Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist

被引:2
|
作者
Badr, Nahla M. [1 ,2 ]
Zaakouk, Mohamed [1 ,3 ]
Zhang, Qi [4 ]
Kearns, Daniel [5 ]
Kong, Anthony [1 ,6 ]
Shaaban, Abeer M. [1 ,5 ,7 ]
机构
[1] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, England
[2] Menoufia Univ, Fac Med, Dept Pathol, Shibin Al Kawm, Egypt
[3] Cairo Univ, NCI, Canc Pathol Dept, Giza, Egypt
[4] Shuwen Biotech Co Ltd, Hangzhou, Zhejiang, Peoples R China
[5] Queen Elizabeth Hosp Birmingham, Birmingham, England
[6] Kings Coll London, London, England
[7] Univ Birmingham, Queen Elizabeth Hosp Birmingham, Dept Cellular Pathol, Canc & Genom Sci, Birmingham B15 2TT, England
关键词
breast cancer; HER2; HER2-low; Ki67; oestrogen receptor; progesterone receptor; TUMOR-INFILTRATING LYMPHOCYTES; DEATH-LIGAND; ARTIFICIAL-INTELLIGENCE; PD-L1; EXPRESSION; SP142;
D O I
10.1111/his.15193
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
BackgroundThere are limited data on the role of multigene tests and their correlation with immunohistochemistry (IHC), especially on core biopsy. MammaTyper is a quantitative conformite Europeeanne (CE) marked, National Institute for Health and Care excellence (NICE) approved, in in vitro diagnostic quantitative real-time polymerase chain reaction (RT-qPCR) test for assessment of mRNA expression of four biomarkers (ESR1, PGR, ERBB2, MKI67).MethodsWe evaluated the concordance of MammaTyper with oestrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 by IHC on 133 core needle biopsies of breast cancer. HER2 was positive if IHC 3+ or 2+ and fluorescence in situ hybridization (FISH)-amplified. Global and hotspot Ki67 expression was analysed using a cutoff of >= 20% assessed manually and by digital image analysis. Agreements were expressed as overall percent agreement (OPA), positive percent agreement (PPA), negative percent agreement (NPA), and Cohen's kappa.ResultsRT-qPCR results of ESR1 were highly concordant with IHC with OPA of 94.7% using 1% cutoff and 91.7% when the low ER-positive category was included. The PPA and NPA between RT-qPCR and IHC for PR was 91.5% and 88.0%, respectively, when using the 1% cutoff. For ERBB2/HER2, the OPA was 95% and the PPA was 84.6%. 40 of 72 HER2 IHC score 0 tumours were classified as ERBB2 low. Best concordance between MKI67 by MammaTyper and Ki67 IHC was achieved using hotspot digital image analysis (OPA: 87.2%, PPA: 90.6%, NPA: 80%).ConclusionRT-qPCR-based assessment of the mRNA expression of ESR1, PGR, ERBB2, and MKI67 showed high concordance with IHC, suggesting that the MammaTyper test on core needle biopsies represents a reliable, efficient, and reproducible alternative for breast cancer classification and refining HER2 low categorisation. Comparison of ER, PR, HER2 expression by immunohistocgemistry and MammaTyper (R) RT-qPCR image
引用
收藏
页码:437 / 450
页数:14
相关论文
共 50 条
  • [1] Comparison of ER, PR, HER2 and Ki67 expression by MammaTyper® RT-qPCR and immunohistochemistry (IHC) on needle core biopsies of breast cancer
    Shaaban, A.
    Badr, N.
    Zaakouk, M.
    Kearns, D.
    Kong, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S87 - S88
  • [2] Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer
    Lili Chen
    Yanyang Chen
    Zhongpeng Xie
    Jiao Luo
    Yuefeng Wang
    Jianwen Zhou
    Leilei Huang
    Hongxia Li
    Linhai Wang
    Pei Liu
    Man Shu
    Wenhui Zhang
    Zunfu Ke
    Breast Cancer Research and Treatment, 2022, 194 : 517 - 529
  • [3] Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer
    Chen, Lili
    Chen, Yanyang
    Xie, Zhongpeng
    Luo, Jiao
    Wang, Yuefeng
    Zhou, Jianwen
    Huang, Leilei
    Li, Hongxia
    Wang, Linhai
    Liu, Pei
    Shu, Man
    Zhang, Wenhui
    Ke, Zunfu
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 194 (03) : 517 - 529
  • [4] Assessment of the dynamic range and quantitative potential of ER, PR, HER2 and Ki67 gene expression by RT-qPCR
    Gasior, A.
    Gorniak, J.
    Howard, K.
    Harrison, M.
    Gough, L.
    Rollinson, S.
    Pounce, Z.
    Wegscheider, A.
    Niendorf, A.
    VIRCHOWS ARCHIV, 2024, 485 : S54 - S54
  • [5] Comparison of RT-qPCR with consensus immunohistochemistry by three pathologists for ER, PR, HER2 and Ki-67 in Chinese breast cancer patients
    Teng, X.
    Li, X.
    Xu, S.
    Zhang, J.
    Hartmann, K.
    Laible, M.
    Hipfel, R.
    Bai, Y.
    Ba, X.
    Wu, Z.
    Wirtz, R. M.
    Liu, S.
    Ugur, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [6] Comparison of ESR1, PGR, HER2 and KI67 expression by central IHC and MammaTyper® RT-qPCR kit in the FinHer trial
    Wirtz, Ralph M.
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Isola, Jorma
    Kataja, Vesa
    Bono, Petri
    Turpeenniemi-Hujanen, Taina
    Jyrkkio, Sirkuu
    Sitho, Harri
    Eidt, Sebastian
    Sahin, Ugur
    Joensuu, Heikki
    CANCER RESEARCH, 2015, 75
  • [7] Employing semi-quantitative methods to classify breast cancer markers (ER, PR, HER2, Ki67) expression, using the RT-qPCR based APIS Breast Cancer Subtyping Kit.
    Gasior, Anna
    Wegscheider, Anne-Sophie
    Paveley, Jack
    Howard, Kimberly Jane
    Harrison, Mathew
    Gough, Leanne
    Gorniak, Joanna
    Rollinson, Sara
    Pounce, Zoe
    Niendorf, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Concordance/discordance rates of HER2, ER, PR, and Ki67 in matched pair samples of primary (PBC) and metastatic breast cancer (MBC) tissues when comparing IHC with MammaTyper® RT-PCR kit
    Wallwiener, Markus
    Hartkopf, Andreas
    Deutsch, Thomas
    Sotiris, Lakis
    Taran, Florin-Andrei
    Trumpp, Andreas
    Wirtz, Ralph
    Schneeweiss, Andreas
    CANCER RESEARCH, 2015, 75
  • [9] Validating the APIS Breast Cancer Subtyping Kit: mRNA Expression of ER, PR, HER2, and Ki67 Compared to Immunohistochemistry in 374 Breast Cancer Core Needle Biopsies
    Gasior, A.
    Wegscheider, A.
    Kramme, I.
    Behr, M.
    Howard, K.
    Gorniak, J.
    Rollinson, S.
    Voss, A.
    Ulm, B.
    Niendorf, A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (11): : S140 - S140
  • [10] Clinical assessment of immunohistochemistry, digital image quantification and AQUA for breast biomarkers ER, PR, HER2 and Ki67
    Gandy, M.
    Stone, K.
    Allen, D.
    Jones, P.
    Miller, K.
    Hamoudi, R.
    Falzon, M.
    Wells, C.
    VIRCHOWS ARCHIV, 2014, 465 : S114 - S114